DATASET
raw_read_counts_KELLY_invivo_screen.xlsx (444.89 kB)
DATASET
genome_scale_screen_avana-1-0_v1_MYCN_neuroblastoma_all_gene_data.csv (6.01 MB)
DATASET
genome_scale_screen_avana-1-0_v1_MYCN_neuroblastoma_secondary_screen_gene_list.csv (163.97 kB)
DATASET
genome_scale_screen_avana-1-0_v1-gene_effect_scores.csv (95.75 MB)
DATASET
raw_read_counts_SIMA_dCas9_Timecourse.xlsx (507.07 kB)
DATASET
raw_read_counts_KELLY_AnnexinV_Screen.xlsx (337.29 kB)
DATASET
raw_read_counts_SKNDZ_dCAS9_TimeCourse.xlsx (424.55 kB)
DATASET
raw_read_counts_SKNDZ_AnnexinV_Screen.xlsx (343.72 kB)
DATASET
raw_read_counts_CHP212_dCAS9_TimeCourse.xlsx (427.56 kB)
DATASET
raw_read_counts_KELLY_dCAS9_TimeCourse.xlsx (423.99 kB)
DATASET
raw_read_counts_CHP212_Cas9_Timecourse.xlsx (441.03 kB)
DATASET
raw_read_counts_SKNDZ_Cas9_Timecourse.xlsx (419.94 kB)
DATASET
raw_read_counts_SIMA_Cas9_timecourse.xlsx (442.23 kB)
DATASET
raw_read_counts_KELLY_Cas9_Timecours.xlsx (546.77 kB)
DATASET
secondary-screen-all-data_v2-dcas9-cn-uncorrected-gene-summary.tsv (983.21 kB)
DATASET
secondary-screen-all-data_v2-cas9-cn-corrected-gene-summary.tsv (1.42 MB)
DATASET
secondary-screen-all-data_v2-guide-mapping.csv (400.51 kB)
DATASET
ChronosJan16Cas9_gene_effect_unscaled.csv (107.74 kB)
DATASET
ChronosJan16Cas9_cell_line_efficacy.csv (0.12 kB)
DATASET
ChronosJan16Cas9_cell_line_growth_rate.csv (0.11 kB)
1/0
CRISPR screens identify selective modulation of a pan-essential protein as a therapeutic strategy in MYCN-amplified neuroblastoma
Download all (110.82 MB) This item is shared privately
dataset
modified on 2020-05-09, 18:31 We were interested in whether we could use the primary DepMap dataset, inclusive of the Pediatric Cancer Dependency Map, to identify putative dependencies in MYCN- neuroblastoma which are dispensable in other cancer cell lines. We then used secondary CRISPR screens to identify genes which when deleted are rapidly cytotoxic and validate in vivo, as these targets might have the efficacy of a conventional cytotoxic chemotherapy but with more selectivity. Here we use time course CRISPR and CRISPRi depletion screens, a positive selection cell death screen, and an in vivo screen to identify the nuclear export factor NXT1 as a novel dependency in MYCN-amplified neuroblastoma.
